NEOG
$9.27
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally.
Recent News
Option Care Health, CooperCompanies, Neogen, GoodRx, and Fortrea Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.
3 Stocks Under $50 That Fall Short
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
Sector Update: Health Care Stocks Retreat Late Afternoon
Health care stocks declined late Monday afternoon with the NYSE Health Care Index falling 1.2% and t
Zoetis Genomics Deal Deepens Precision Animal Health Growth Story
Zoetis (NYSE:ZTS) has entered into a definitive agreement to acquire Neogen Corporation's animal genomics business. The planned acquisition is intended to expand Zoetis's global genomics capabilities in Precision Animal Health. The deal is expected to strengthen Zoetis's position in predictive and individualized livestock care worldwide. Zoetis focuses on medicines, vaccines and diagnostic tools for pets and livestock, and the Neogen genomics unit fits into that broader animal health...
Neogen (NEOG) Valuation Check After Earnings Beat And Strong Investor Response
Neogen (NEOG) is back on investors’ radar after reporting quarterly results that beat analysts’ expectations on both revenue and earnings per share, even though revenue saw a slight year over year decline. See our latest analysis for Neogen. The share price has had a sharp run in recent months, with a 30 day share price return of 8.5% and a 90 day share price return of 87.79%. The 1 year total shareholder return of 11.74% compares with much weaker 3 and 5 year total shareholder returns, which...